Evidence map›Paper›PMID 29295866›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2018

Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure.

Allison M Johnson, James P Roach, Anna Hu, Svetlana M Stamatovic, Michal R Zochowski, Richard F Keep, Anuska V Andjelkovic

RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Deceiving the gatekeepers: virus modulation of gap junctions.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  7. MAPK signaling and angiopoietin-2 contribute to endothelial permeability in capillary malformations.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Allison M JohnsonDepartment of Pathology, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
James P RoachNeuroscience Graduate Program, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
Anna HuDepartment of Pathology, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
Svetlana M StamatovicDepartment of Pathology, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
Michal R ZochowskiDepartment of Physics and Biophysics, University of Michigan, Ann Arbor, Michigan, USA.
Richard F KeepDepartment of Neurosurgery, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
Anuska V AndjelkovicDepartment of Pathology, Medical School, University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan–Ann Arbor · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Role of Cx43 signaling in cerebral cavernous malformation type-3 lesionR21NS098066 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDJELKOVIC-ZOCHOWSKA, ANUSKA V. · 2016 to 2017
$413k
NCI NIH HHS P30 CA046592NINDS NIH HHS R21 NS098066
6 · The paper itself

Abstract

Familial cerebral cavernous malformations type III (fCCM3) is a disease of the cerebrovascular system caused by loss-of-function mutations in ccm3 that result in dilated capillary beds that are susceptible to hemorrhage. Before hemorrhage, fCCM3 lesions are characterized by a hyperpermeable blood-brain barrier (BBB), the key pathologic feature of fCCM3. We demonstrate that connexin 43 (Cx43), a gap junction (GJ) protein that is incorporated into the BBB junction complex, is up-regulated in lesions of a murine model of fCCM3. Small interfering RNA-mediated ccm3 knockdown (CCM3KD) in brain endothelial cells in vitro increased Cx43 protein expression, GJ plaque size, GJ intracellular communication (GJIC), and barrier permeability. CCM3KD hyperpermeability was rescued by GAP27, a peptide gap junction and hemichannel inhibitor of Cx43 GJIC. Tight junction (TJ) protein, zonula occludens 1 (ZO-1), accumulated at Cx43 GJs in CCM3KD cells and displayed fragmented staining at TJs. The GAP27-mediated inhibition of Cx43 GJs in CCM3KD cells restored ZO-1 to TJ structures and reduced plaque accumulation at Cx43 GJs. The TJ protein, Claudin-5, was also fragmented at TJs in CCM3KD cells, and GAP27 treatment lengthened TJ-associated fragments and increased Claudin 5-Claudin 5 transinteraction. Overall, we demonstrate that Cx43 GJs are aberrantly increased in fCCM3 and regulate barrier permeability by a TJ-dependent mechanism.-Johnson, A. M., Roach, J. P., Hu, A., Stamatovic, S. M., Zochowski, M. R., Keep, R. F., Andjelkovic, A. V. Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure.

Indexed as

AnimalsBlood-Brain BarrierCell LineClaudin-5Connexin 43Disease Models, AnimalEndothelium, VascularGap JunctionsHemangioma, Cavernous, Central Nervous SystemHumansMiceMice, KnockoutPermeabilityTight JunctionsZonula Occludens-1 ProteinClaudin-5Cldn5 protein, mouseConnexin 43Tjp1 protein, mouseZonula Occludens-1 Proteincell-cell interactionPDCD10permeabilityzonula occludens-1

Identifiers

PMID29295866
PMCPMC5901390
OpenAlexW2781738339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.